Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
02 mai 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its first...
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
24 avr. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President...
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
07 mars 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter...
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
22 févr. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth...
Elutia Regains Compliance with Nasdaq Listing Requirements
10 janv. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq’s market value of listed securities requirement and...
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance
18 déc. 2023 08h00 HE
|
Elutia Inc.
510(k) filing follows FDA feedback from successful pre-submission meeting SILVER SPRING, Md., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k)...
Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results
13 nov. 2023 16h05 HE
|
Elutia Inc.
- Anticipate 510(k) filing for transformational Drug-Eluting Biomatrix CanGarooRM in Fourth Quarter SILVER SPRING, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a...
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million
09 nov. 2023 08h30 HE
|
Elutia Inc.
- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting...
Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
06 nov. 2023 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third...
Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference
20 sept. 2023 08h30 HE
|
Elutia Inc.
SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President...